On Thursday, ACADIA Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
Discover The 3 Keys To Successful Stock Investing
The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria.
ACADIA Pharmaceuticals is currently extended beyond a proper buy zone after clearing the 20.68 buy point in a cup without handle.
One weak spot is the company's 64 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company reported 10% EPS growth. Top line growth increased 19%, up from 12% in the prior quarter. That marks one quarter of accelerating revenue gains.
ACADIA Pharmaceuticals earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
